Featured Company News - Titan Pharmaceuticals Announces First Patient Treatment for Parkinson's Disease in Phase-1/2 Trial with Ropinirole Implant
Research Desk Line-up: Merus Post Earnings Coverage
LONDON, UK / ACCESSWIRE / October 13, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan"), following which we have published a free report that can be viewed by signing up at http://protraderdaily.com/optin/?symbol=TTNP. The Company announced on October 11, 2017, the treatment of the first patient in Phase-1/2 trial, designed to evaluate the efficacy of the Ropinirole implant intended for the treatment of the signs and symptoms of idiopathic Parkinson's disease. For immediate access to our complimentary reports, including today's coverage, register for free now at:
Discover more of our free reports coverage from other companies within the Biotechnology industry. Pro-TD has currently selected Merus N.V. (NASDAQ: MRUS) for due-diligence and potential coverage as the Company announced on September 19, 2017, its financial results for Q2 2017 which ended on June 30, 2017, and also provided a corporate and clinical update. Tune in to our site to register for a free membership, and be among the early birds that get our report on Merus when we publish it.
At Pro-TD, we make it our mission to bring you news that matter about the stock you follow. Today, our research desk covers a blog story on TTNP; also brushing on MRUS. Go directly to your stock of interest and access today's free coverage at:
Titan is dedicated to developing proprietary therapeutics for the treatment of various chronic diseases by leveraging its ProNeura™ long-term, continuous drug delivery technology.
About the Ropinirole Implant
Ropinirole is a dopamine agonist which is currently available for daily or frequently dosed oral formulations for the treatment of Parkinson's disease symptoms and restless leg syndrome. It is often used in combination with L-dopa to help control severe motor complications and dyskinesias that normally occur in patients after many years of L-dopa treatment. The medication is known to cause certain side effects, which as per clinical studies, is due to the fluctuating medication levels of oral formulations.
To overcome this, Titan has developed its Ropinirole implant utilizing its ProNeura drug delivery technology. The impact is designed for the long-term, uninterrupted, and continuous delivery of Ropinirole HCL for the treatment of signs and symptoms of Parkinson's disease. Continuous delivery of Ropinirole could possibly reduce the severe motor complications experienced by patients on oral daily-dosed formulations of the medication.
Dr. Aaron Ellenbogen of the Michigan Institute of Neurological Disorders, who is also the Principal Investigator at the first trial site, near Detroit, Michigan, shared his thoughts on the issue. He mentioned that patients on oral formulations of dopamine and dopamine agonists often develop serious motor complications and dyskinesias. This is caused by the daily pattern of peak-trough levels of medication in the blood, duration as well as the severity of the disease, and higher-dosage requirement of levodopa. Nevertheless, a long-acting dopamine agonist with a flat pharmacokinetic profile can help in minimizing these complications.
Parkinson's disease affects over 10 million people globally. This represents a need for newer and better treatments for the disease. Thus, Dr. Ellenbogen looks forward to further evaluating the potential of a Ropinirole implant in this study.
About the Phase-1/2 Trial
Currently, the trial is being conducted at three clinical research sites in the US which specialize in the treatment of Parkinson's disease. It is an open-label, sequential, dose escalation study, with the enrollment of around 20 subjects with idiopathic Parkinson's disease. As part of the trial, patients on a stable dose of L-dopa plus oral Ropinirole will get their oral Ropinirole switched to Ropinirole implants for three months of treatment.
Primary Objective of the Study - The primary objectives of the study are to illustrate the pharmacokinetic profile of the Ropinirole implants in order to evaluate their safety and tolerability, and to explore prospective signals of efficacy using established disease-specific assessment scales.
Study Completion Schedule - Titan expects initial data from the first cohort of patients in the first quarter of 2018 while the study completion is targeted for the end of 2018.
Forward Looking Remarks from Titan's Chief Development Officer
Kate Beebe, PhD, Titan's Executive Vice President and Chief Development Officer, expressed her pleasure at the treatment of the first patient in this critical Phase-1/ 2 trial, which is designed to evaluate the pharmacokinetic profile and the safety and tolerability of the Ropinirole implant. Titan has developed the Ropinirole implant to deliver continuous, non-fluctuating levels of this dopamine agonist for up to three months for patients suffering from Parkinson's disease. Beebe believes that Titan's Ropinirole implant has the potential to offer patients significant benefits over the existing daily and more frequently dosed oral formulations of Ropinirole. She, thus, looks forward to continuing the enrollment of more and more subjects in this study.
Last Close Stock Review
On Thursday, October 12, 2017, the stock closed the trading session at $2.10, declining 6.67% from its previous closing price of $2.25. A total volume of 217.36 thousand shares have exchanged hands, which was higher than the 3-month average volume of 141.98 thousand shares. Titan Pharma's stock price soared 31.25% in the last one month and 7.69% in the past three months. The stock currently has a market cap of $40.15 million.
Pro-Trader Daily (Pro-TD) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. PRO-TD has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
PRO-TD has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by PRO-TD. PRO-TD is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
PRO-TD, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. PRO-TD, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, PRO-TD, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither PRO-TD nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://protraderdaily.com/disclaimer/.
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: (917) 341.4653
Office Address: Mainzer Landstrasse 50 Frankfurt am Main, Germany 60325
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: Pro-Trader Daily
© 2017 Accesswire. All Rights Reserved.